Out-licensing: Pegylated Filgrastim

Latest: Watch here for details of new products and services.

About Us: Pharmalicensing - Partnering solutions for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Deal Negotiation; PL Intelligence; Reports; Comparison
PL Intelligence: Overview; Industry news; Deals review; Press releases; Articles
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs
Contact Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd

Out-licensing
View

Pegylated Filgrastim

Peg GCSF

Mechanism of action

in the treatment of chemotherapy-induced neutropenia

Full description

· 2^nd Pegfilgrastim in the world

· G-CSF is N-terminally pegylated with 20 kDa PEG molecule

· In house pegylation, followed by purification

· Series of tests are performed to establish product quality, identity and efficacy comparable to innovator like peptide mapping, RP-HPLC, SDS page, mass spectroscopy and bioassay.

· Comparative pharmacokinetic study with the innovator in Europe

· Product is available in liquid bulk and formulation of 6 mg/ml in PFS

Registration document is available in CTD format

Development status

Registered

Type of business relationship sought

Out-licensing.

Licensing contact

Mr. Milan Doshi
Asst General Manager
Business Development

Contact directly

Company details

Intas BioPharmaceuticals

Research driven, human biotherapeutics company focused on rDNA products offering out-licensing of biogeneric bulk-API and finished formulations, contract research and contract manufacturing services.

View profile

Visit website

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Progressive Elevated Gene-3 (PEG-3) Induces Aggressive Cancer Phenotype and Regulates Angiogenesis

Methods for identifying compounds that inhibit the binding of p75 to FAP-1

Inhibition of cataracts and other disorders

C-Terminal p53 palindromic peptide that induces apoptosis of cells with aberrant p53 and uses thereof

Related categories

Industry sector: Biotechnology; Pharmaceutical
Therapeutic target: Blood and forming organs; Oncology / Cancer side effects; Hospital and Surgery; Oncology

Clients in focus...

Get the Flash Player to see this rotator.

Press releases: Pharmalicensing current industry press releases.

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us